VedaBio has entered into agreement with Mammoth Biosciences to enhance its CRISPR-based molecular detection platform for ...

It has long been understood that orchard automation is the key for industry’s profitability and sustainability. As part of ...

CRISPR technology could one day create “designer babies, ” raising major ethical and social inequality concerns.

VedaBio announces non-exclusive license agreement with Mammoth Biosciences for use of select CRISPR-based technologies in diagnostic applications ...

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. CRISPR Therapeutics AG ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

A study, published in the journal Frontiers in Genome Editing, outlines a method for editing single plant cells from sterile ...

The nonexclusive license potentially broadens VedaBio's platform while making it simpler and more cost-effective.

Multisystemic smooth muscle dysfunction syndrome (MSMDS) is a rare condition associated with stroke, aortic dissection ...

More than a decade ago, scientists harnessed a bacterial molecular machine that identifies and cuts specific sections of DNA, ...

The field of microbiology has emerged as a cornerstone for green technology, playing a crucial role in fostering sustainable ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...